Skip to main content

DOD Investing in Cannabinoids

Department of Defense Invests $1.3 Million to Study a Cannabinoid that May Help Alleviate Symptoms of Autism.

By Geoff on January 6, 2019.

Autism spectrum disorder (ASD), is a developmental and behavioral disorder that affects human communication and behavior. One in 68 children have ASD and there are limited treatment options. The agents available (such as antipsychotics) have a number worrisome of side effects that limit their use.

The disorder also affects military readiness which is why the department of defense is interested in improving treatment.

The Future of Cannabinoids


A cannabinoid called Cannabidivarin (CBDV) may help treat symptoms such as irritability and repetitive behavior that are common in ASD. CBDV is a homolog of CBD, meaning it is closely chemically related, and differs only by the presence of one methylene bridge (-CH2-). Giving the DOD reason to invest into this type of cannabinoid research.

CBDv & Hemp

Many hemp strains share common cannabinoid profiles as THC-rich “cannabis” strains, this includes CBDv and 100+ identified plant-based cannabinoids. The research into cannabinoids and their role in human physiology has been growing exponentially since the first cannabinoid discovery in the 1940’s.

A new door is now opening for the future of hemp breeding, where the emphasis is placed in bringing out the other cannabinoids like CBDv, deviating from a model that has been dictated by consumer demand for high-THC containing plants since the prohibition of cannabis sativa L.

The study will be conducted at Montefiore Health System in New York City, and will be led by Eric Hollander MD, a psychiatrist and Director of the Autism and Obsessive-Compulsive Spectrum Program at Montefiore Medical Center.

Leave a Reply